Techne Corporation  

(Public, NASDAQ:TECH)   Watch this stock  
Find more results for Howard Blood
92.03
-0.24 (-0.26%)
Jul 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 91.20 - 92.78
52 week 73.38 - 96.96
Open 92.50
Vol / Avg. 0.00/151,120.00
Mkt cap 3.40B
P/E 30.26
Div/yield 0.31/1.35
EPS 3.04
Shares 37.00M
Beta 0.60
Inst. own 95%
Aug 4, 2014
Q4 2014 Techne Corp Earnings Release (Estimated) Add to calendar
Jun 10, 2014
Techne Corp at William Blair & Company LLC Growth Stock Conference
Apr 28, 2014
Q3 2014 Techne Corp Earnings Release
Apr 28, 2014
Q3 2014 Techne Corp Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 33.11% 36.24%
Operating margin 47.90% 51.02%
EBITD margin - 54.99%
Return on average assets 15.55% 15.03%
Return on average equity 16.64% 15.94%
Employees 789 -
CDP Score - -

Address

614 McKinley Place N.E.
MINNEAPOLIS, MN 55413-2610
United States - Map
+1-612-3798854 (Phone)
+1-612-3796580 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

TECHNE Corporation, is engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted through its wholly owned subsidiaries, Research and Diagnostic Systems, Inc. (R&D Systems), Boston Biochem, Inc. (Boston Biochem), and BiosPacific, Inc. (BiosPacific). The Company operates in two segments: biotechnology and hematology. The Company's biotechnology reporting segment develops, manufactures and sells biotechnology research and diagnostic products world-wide. The Company's hematology reporting segment, which consists of R&D Systems' Hematology Division, develops and manufactures hematology controls and calibrators for sale worldwide. In July 2014, Techne Corp acquired Novus Biologicals.

Officers and directors

Robert V. Baumgartner CPA Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Charles R. Kummeth President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Roger C. Lucas Ph.D. Independent Vice Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
James T. Hippel Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
David Eansor Senior Vice President - Novus Biologicals
Age: 53
Bio & Compensation  - Reuters
Kevin Reagan Senior Vice President - Biotech
Age: 61
Bio & Compensation  - Reuters
Marcel Veronneau Senior Vice President - Clinical Controls
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
J. Fernando Bazan Ph.D. Chief Technology Officer
Age: 53
Bio & Compensation  - Reuters
Howard V. O'Connell Lead Independent Director
Age: 83
Bio & Compensation  - Reuters
Harold J. Wiens Director
Age: 68
Bio & Compensation  - Reuters